Résumé
Le proto-oncogène HER2 code pour une glycoprotéine transmembranaire possédant une activité tyrosinekinase qui conduit à une activation de la transcription nucléaire de gènes régulant la progression du cycle cellulaire. Dans le cancer du sein, la protéine HER2 est surexprimée dans 18 à 20 % des cas. Une étude immunohistochimique est réalisée sur 50 prélèvements de tumeurs du sein, colligées dans la wilaya d’Oran (ouest algérien) dans le but d’évaluer l’expression de la protéine HER2. Les résultats de l’analyse immunohistochimique montrent que 30 % des cas de cancers du sein présentent un statut HER2 positif et 70 % des cas un statut HER2 négatif. Les résultats obtenus montrent que l’étude du profil de l’expression de la protéine HER2 chez les femmes atteintes d’un cancer du sein semble très importante dans la prédiction, le pronostic et la prise en charge.
Abstract
The HER2 proto-oncogene encodes a transmembrane glycoprotein with tyrosine-kinase activity which leads to activation of the nuclear transcription of genes regulating cell cycle progression. In breast cancer, the HER2 protein is overexpressed in 18 to 20% of cases. An immunohistochemical study was performed on 50 samples of breast tumours, collected in the Wilaya of Oran (western Algeria) to evaluate expression of the HER2 protein. The results of the immunohistochemical analysis showed that 30% of cases of breast cancer have HER2 positive status and 70% have HER2 negative status. The results obtained show that the study of HER2 protein expression in breast cancer in women appears to be very important in prediction and prognosis.
This is a preview of subscription content, log in via an institution to check access.
Références
Yarden Y, Sliwkowski M (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
Schroeder W, Biesterfeld S, Zillessen S, Rath W (1997) Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 17:2799–2802
Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V (2002) Évaluation immunohistochimique du statut HER2 dans les carcinomes mammaires infiltrants: mise au point du protocole technique et de la lecture des résultats — recommandations. Ann Pathol 22(2):150–157
Wolff AC, Hammond ME, Schwartz JN, et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145
Slamon DJ, Clark GM, Wong SG, et al (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Pritchard KI, Shepherd LE, O’Malley FP, et al (2006) The National Cancer Institute of Canada Clinical Trials Group. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. N Engl J Med 354:2103–2111
American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) (2007) Guideline Summary: American Society of ClinicalOncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor HER2 testing in breast cancer. J Oncol Pract 3(1):48–50
Laudadio J, Quigley DI, Tubbs R, Wolff DJ (2007) HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn 7(1):53–64
Blaizel O, Ferland A, Morin J (2006) À la recherche des patientes présentant un cancer HER2/neu positif: analyse rétrospective. Pharmactuel 39(5):252–260
Enzing C, van den Akker-van Marle E, Detmar S, et al (2006) Case studies and cost-benefit analysis of HER2 and TPMT in four EU member states. Part 2 of an ESTO study on pharmacogenetics and pharmacogenomics: State of the art and social and economic impacts. Technical Report EUR 22214 EN. Luxembourg: Institute for Prospective Technological Studies (IPTS); European Commission, Joint Research Centre; European Science and Technology Observatory (ESTO). Disponible à: ftp://ftp.jrc.es/pub/EURdoc/eur22214wp2.pdf
Lebeau A (2006) HER2 testing in breast cancer: opportunities and challenges. Breast Care, 1(2):69–76
Lee A, Park WC, Yim HW, et al (2007) Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast. Jpn J Clin Oncol 37(9):708–714
Dendukuri N, Khetani K, McIsaac M, Brophy J (2007) Testing for HER2-positive breast cancer: a systematic review and costeffectiveness analysis. CMAJ 176(10):1429–1434
Dendukuri N, Brophy J (2006) Testing for HER2 positive breast cancer: a cost-effectiveness analysis. Montréal, Qc: McGill University Health Centre (MUHC)
Gosselin C, Dagenais P (2008) Performance diagnostique des techniques de détermination du statut HER-2 dans le cancer du sein. AETMIS (Agence d’évaluation des technologies et des modes d’intervention en santé), vol 4, no 3
Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor and target for therapy. Oncologist 3:237–252
Benz CC, Scott GK, Sarup JC (1992) Estrogen-dependent, tamoxifen-resistant tumorogenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95
Hudziak RM, Schlessinger J, Ullrich A (1987) Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159–7163
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Medjdoub, A., Tahari, Z., Sahraoui, T. et al. Étude du profil d’expression de la protéine HER2 dans 50 cas de cancers mammaires dans la wilaya d’Oran. J Afr Cancer 1, 127–129 (2009). https://doi.org/10.1007/s12558-009-0025-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12558-009-0025-0